Summit Therapeutics (SMMT) Income from Continuing Operations (2017 - 2024)
Summit Therapeutics' (SMMT) quarterly Income from Continuing Operations came in at 72919000.0 in Q4 2024, down 86.46% YoY from 538553981.68 in Q1 2024, and down 19.87% on a QoQ basis from 60833000.0 in Q3 2024.
Powered by 
Analysis
Summit Therapeutics (SMMT) Income from Continuing Operations (2017 - 2024) Analysis & Trends
Summit Therapeutics (SMMT) has 8 years of Income from Continuing Operations data on file, last reported at 72919000.0 in Q4 2024.
- Quarterly Income from Continuing Operations fell 86.46% year-over-year to 72919000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 241981000.0 (up 61.36% YoY) and the FY2024 annual result came in at 1903746000.0, down 209.59% from the prior year.
- Income from Continuing Operations retreated to 72919000.0 in Q4 2024, from 60833000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 6328567.59 in Q1 2020 to a low of 544513000.0 in Q1 2023.
- A 5-year average of 54321028.38 and a median of 22829000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations slumped 2324.91% — and 2024, when it surged 91.64%.
- Tracing SMMT's Income from Continuing Operations over 5 years: stood at 13541000.0 in 2020, then slumped by 100.13% to 27099000.0 in 2021, then grew by 14.38% to 23203000.0 in 2022, then tumbled by 68.54% to 39107000.0 in 2023, then tumbled by 86.46% to 72919000.0 in 2024.
- The last three Income from Continuing Operations figures came in at 72919000.0 (Q4 2024), 60833000.0 (Q3 2024), and 62719000.0 (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Summit Therapeutics | 13.67 Bn | 12.98 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -65.62 Mn |
| Sep 30, 2024 | -60.83 Mn |
| Jun 30, 2024 | -62.72 Mn |
| Mar 31, 2024 | -45.51 Mn |
| Dec 31, 2023 | -36.21 Mn |
| Sep 30, 2023 | -20.49 Mn |
| Jun 30, 2023 | -15.79 Mn |
| Mar 31, 2023 | -536.19 Mn |
| Dec 31, 2022 | -20.30 Mn |
| Sep 30, 2022 | -16.94 Mn |
| Jun 30, 2022 | -12.69 Mn |
| Mar 31, 2022 | -22.16 Mn |
| Dec 31, 2021 | -27.10 Mn |
| Sep 30, 2021 | -19.60 Mn |
| Jun 30, 2021 | -24.42 Mn |
| Mar 31, 2021 | -17.49 Mn |
| Dec 31, 2020 | -13.54 Mn |
| Sep 30, 2020 | -17.74 Mn |
| Jun 30, 2020 | -15.28 Mn |
| Mar 31, 2020 | -6.33 Mn |